Working… Menu

Continuous Subcutaneous Hydrocortisone Infusion In Addison`s Disease and Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01840189
Recruitment Status : Completed
First Posted : April 25, 2013
Last Update Posted : February 1, 2017
Information provided by (Responsible Party):
Haukeland University Hospital

Tracking Information
First Submitted Date  ICMJE April 23, 2013
First Posted Date  ICMJE April 25, 2013
Last Update Posted Date February 1, 2017
Study Start Date  ICMJE May 2013
Actual Primary Completion Date December 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 23, 2013)
nocturnal hypoglycemic events [ Time Frame: 4 months ]
severe hypoglycemia (needs for another person's assistance, blood glucose ≤ 3.1 mmol ⁄ L or prompt recovery after oral carbohydrate, i.v glucose or glucagon administration) and insulin requirement
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT01840189 on Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: April 23, 2013)
  • o Nocturnal glycemic variability [ Time Frame: 4 months ]
    monitored by continuous glucose monitor system
  • hormone and metabolic profile [ Time Frame: 4 months ]
    • Hormone levels : insulin like growth factor 1, growth hormone
    • Steroid metabolism: adrenocorticotropic hormone , cortisol
    • Metabolic profile: fructosamine, HBA1C, lipid levels, C reactive protein , homeostasis model assessment index
  • o Subjective health status [ Time Frame: 4 months ]
    Self administration of questionnaires
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Continuous Subcutaneous Hydrocortisone Infusion In Addison`s Disease and Type 1 Diabetes
Official Title  ICMJE Continuous Subcutaneous Hydrocortisone Infusion In Addison`s Disease and Type 1 Diabetes
Brief Summary

The conventional glucocorticoid replacement therapy in primary adrenal insufficiency (Addison's disease) renders the cortisol levels unphysiological, which may cause symptoms and long-term complications.

The majority of Addison's patients have other organ-specific autoimmune disease, which poses challenges to the replacement therapy. Of particular interest is the combination of Addison`s disease and type 1 diabetes, since cortisol affects glucose homeostasis. The clinical experience is that this subgroup of patients is difficult to treat, but very little research has been done to understand and improve their situation.

Glucocorticoid replacement is technically feasible by continuous subcutaneous hydrocortisone infusion, and can mimic the normal diurnal cortisol rhythm. This pilot study aims to further evaluate continuous subcutaneous hydrocortisone infusion treatment in terms of metabolic effects especially glycemic control in patients with the combination of Addison`s disease and type 1 diabetes in an 5 months cross-over design open clinical pilot study.

Detailed Description

Treatment of Addison`s disease includes glucocorticoid and mineralocorticoid replacement. Despite optimized therapy with these steroids, many patients suffer from impaired quality of life and increased mortality. The etiology of the premature death is complicated and may include a combination of inadequate treatment of adrenal crisis, patient non-compliance, and undetected hypoglycemia, in addition to being associated with increased cardiovascular, malignant, and infectious disease deaths. The relative risk of death for patients with Type 1 Diabetes is 3.8 in Sweden. Having Type 1 diabetes and Addison`s disease significantly increased the risk of death when compared with having adrenal insufficiency alone. The risk for premature death in patients with the combination of Type 1 diabetes and Addison`s disease has not been extensively studied and appears to contribute to a small portion of the increased mortality seen in patients with Addison`s disease.

Cortisol has particularly potent effects on blood glucose levels, otherwise Addison`s disease affects the production of cortisol, an important counterregulatory hormone for hypoglycaemia. Lack of cortisol might increase the risk of hypoglycemic episodes, whereas over-replacement might cause hyperglycemia. Because steroid replacement may cause significant insulin resistance, it is challenging to adjust insulin doses to maintain optimal glycemic control. Little is known about the effects of unphysiological glucocorticoid replacement therapy on glucose and lipid metabolism, but there has been concern about long-term metabolic consequence. Current glucocorticoid replacement results in large fluctuations in the cortisol levels directly influencing glucose homeostasis and, consequently, making accompanying insulin treatment difficult to manage. Different types, regimens and doses of glucocorticoids are now used in adrenal insufficiency, but none approximate the physiological rhythm. Hydrocortisone administration via a subcutaneous pump is a novel strategy that restores circadian cortisol rhythm in most patients.

The study will be open-labelled, cross-over designed, with comparison of two glucocorticoid replacement modalities to glycemic events in randomised order within each patient, as illustrated in figure.

Treatment A is optimised oral hydrocortisone ( Cortef 5 mg) replacement according to Mah et al, and treatment B is continuous subcutaneous hydrocortisone infusion therapy. The patients will be assigned a participation number and randomised to any of two treatment sequences (A-B or B-A). Should the need for an extra glucocorticoid dose occur (intercurrent illness, exercises) during the study, for safety reasons, the patients should administer their previous glucocorticoid and insulin replacement. If the dose of insulin is changed, new testing by self-monitoring of blood glucose and continuous glucose monitor system should be done.

The period of dose adjustments for insulin treatment during both glucocorticoids replacement modalities will take 2 weeks for each and 6 weeks assessment of glycemic control by continuous glucose monitor system, followed by a minimal of one month during which the patients use their previous glucocorticoid replacement and previous insulin therapy (wash-out period).

Patients will be educated in groups, and dose adjustments will be co-ordinated with regular visits at the outpatient clinic/telephone consultation combined with laboratory analyses. After the principal study period participants will be offered a 3 months' continuous subcutaneous hydrocortisone infusion treatment extension period. Infusion gear and Solu-Cortef 50mg/ml infusate will be refunded over the study budget. Hydrocortisone infusion will be given as Solu-Cortef Act-o-Vial 50mg/ml produced by Pfizer. Pump designed for subcutaneous insulin infusion can be used for subcutaneous administration.

glucose levels are stable.

Withdrawal criteria/Adverse Events The patient is free to withdraw at any time. If a patient is having major difficulties managing the infusion pump/equipment/continuous glucose monitor after thorough education and instructions, the investigator will consider withdrawal. In the best interest of the patient, the investigator and the sponsor can decide to withdraw the patient from the study. Compliance of the patients will be checked according to the report from remote control - Patients Diabetes Manager and continuous glucose monitor. Unfortunately, there are available no methods how to follow up the compliance to the oral treatment. If a patient develops conditions meeting the exclusion criteria, the patient will be withdrawn from the study. In case of serious adverse events the patient may be withdrawn from the study.

Any adverse event will be registered and reported to the Norwegian and Swedish Medicines Agency. Any serious adverse events will be reported within 15 days, and in case of lethal or life threatening events immediately. The patients will report any problems or discomfort in the patient diary, any need for extra doses with glucocorticoids will also be documented there. In addition, we ask them to contact the study group directly in case of problems/adverse events between consultations.

The study documentation and research date will be stored 15 years after the termination of the study. After the termination of the study we will notify ethical committee by 90 days and the final report will be prepared and delivered to ethical committee. If needed to terminate the study earlier, we will notify the ethical committee by 15 days.

Statistical considerations The studies are academic, investigator-driven pilot studies, limited in number by expensive techniques and rare diseases.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Addison Disease
  • Type 1 Diabetes
Intervention  ICMJE
  • Other: Cortef
    Treatment A is oral hydrocortisone replacement ( Cortef 5 mg) administered according to weight-adjusted doses for 2 months
  • Other: Solu-cortef

    Treatment B is continuous subcutaneous hydrocortisone infusion with the initial standard dose of 10mg/m2/24hrs. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.

    This part of the study will take 2 months.

Study Arms  ICMJE
  • Active Comparator: Cortef
    Treatment A is oral hydrocortisone replacement( Cortef 5 mg)with weight-adjusted doses as suggested by Mah et al , will take 2 months
    Intervention: Other: Solu-cortef
  • Active Comparator: Solu-cortef
    This is the treatment B by continuous subcutaneous hydrocortisone infusion. Solu-cortef infusion will be given as Solu-Cortef Act-o-Vial 50mg/ml, , produced by Pfizer. Pump designed for subcutaneous insulin infusion can be used for subcutaneous administration.
    Intervention: Other: Cortef
Publications *

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 29, 2016)
Original Estimated Enrollment  ICMJE
 (submitted: April 23, 2013)
Actual Study Completion Date  ICMJE December 2016
Actual Primary Completion Date December 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

- primary Addison`s disease in combination with long-standing Type 1 diabetes

Exclusion Criteria:

  • cardiovascular disease
  • active malignant disease
  • pregnant women
  • pharmacological treatment with glucocorticoids or drugs that interfere with cortisol metabolism (antiepileptics, rifampicin, St. Johns war, estrogens)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Norway
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT01840189
Other Study ID Numbers  ICMJE 2012/2218
2012/005516-26 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Haukeland University Hospital
Study Sponsor  ICMJE Haukeland University Hospital
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Kristian Løvås, MD, PhD Haukeland University Hospital
Principal Investigator: Katerina Simunkova, PhD Haukeland University Hospital
PRS Account Haukeland University Hospital
Verification Date December 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP